Showing posts with label Human Genome. Show all posts
Showing posts with label Human Genome. Show all posts

Thursday, November 8, 2012

Global Genome Effort and Ethnic Groups


Global Genome Effort Seeks Genetic Roots of Disease


By decoding the genomes of more than 1,000 people whose homelands stretch from Africa and Asia to Europe and the Americas, scientists have compiled the largest and most detailed catalog yet of human genetic variation. The massive resource will help medical researchers find the genetic roots of rare and common diseases in populations worldwide. (Credit: National Human Genome Research Institute)
ScienceDaily  — By decoding the genomes of more than 1,000 people whose homelands stretch from Africa and Asia to Europe and the Americas, scientists have compiled the largest and most detailed catalog yet of human genetic variation. The massive resource will help medical researchers find the genetic roots of rare and common diseases in populations worldwide.

The 1000 Genomes Project involved some 200 scientists at Washington University School of Medicine in St. Louis and other institutions. Results detailing the DNA variations of individuals from 14 ethnic groups are published Oct. 31 in the journal Nature. Eventually, the initiative will involve 2,500 individuals from 26 populations.

"With this resource, researchers have a roadmap to search for the genetic origins of diseases in populations around the globe," says one of the study's co-principal investigators, Elaine Mardis, PhD, co-director of The Genome Institute at Washington University. "We estimate that each person carries up to several hundred rare DNA variants that could potentially contribute to disease. Now, scientists can investigate how detrimental particular rare variants are in different ethnic groups."

At the genetic level, any two people are more than 99 percent alike. But rare variants -- those that occur with a frequency of 1 percent or less in a population -- are thought to contribute to rare diseases as well as common conditions like cancer, heart disease and diabetes. Rare variants may also explain why some medications are not effective in certain people or cause side effects such as nausea, vomiting, insomnia and sometimes even heart problems or death.

Identifying rare variants across different populations is a major goal of the project. During the pilot phase of the effort, the researchers found that most rare variants differed from one population to another, and that they developed recently in human evolutionary history, after populations in Europe, Africa, Asia and the Americas diverged from a single group. The current study bears this out.

"This information is crucial and will improve our interpretation of individual genomes," says another of the study's co-principal investigators, Richard K. Wilson, PhD, director of The Genome Institute and a pioneer in cancer genome sequencing. "Now, if we want to study cancer in Mexican Americans or Japanese Americans, for example, we can do so in the context of their diverse geographic or ancestry-based genetic backgrounds."

Results of the new study are based on DNA sequencing of the following populations: Yoruba in Nigeria; Han Chinese in Beijing; Japanese in Tokyo; Utah residents with ancestry from northern and western Europe; Luhya in Kenya; people of African ancestry in the southwestern United States; Toscani in Italy; people of Mexican ancestry in Los Angeles; Southern Han Chinese in China; Iberian from Spain; British in England and Scotland; Finnish from Finland; Colombians in Columbia; and Puerto Rican in Puerto Rico.

All study participants submitted anonymous DNA samples and agreed to have their genetic data included in an online database. To catalog the variants, the researchers first sequenced the entire genome -- all the DNA -- of each individual in the study about five times. Surveying the genome in this way finds common DNA changes but misses many rare variants.
Then, to find rare variants, they repeatedly sequenced the small portion of the genome that contains genes -- about 80 times for each participant to ensure accuracy -- and they looked closely for single letter changes in the DNA sequence called SNPs (for single-nucleotide polymorphisms).

Using special tools developed to analyze and integrate the data, the researchers discovered a total of 38 million SNPs, including more than 99 percent of the variants with at frequency of at least one percent in the participants' DNA samples. They also found numerous structural variations, including 1.4 million short stretches of insertions or deletions and 14,000 large DNA deletions.

SNPs and structural variants can help explain an individual's susceptibility to disease, response to drugs or reaction to environmental factors such as air pollution or stress. Other studies have found an association between small insertions and deletions and diseases such as autism and schizophrenia.

The 1000 Genomes Project has generated massive amounts of genomic data. Simply recording the raw information took up some 180 terabytes of hard-drive space, enough to fill more than 40,000 DVDs. All of the information is freely available on the Internet through public databases.

"This tremendous resource builds on the knowledge of the Human Genome Project," says co-author George Weinstock, PhD, associate director of The Genome Institute. "Scientists and, ultimately, patients worldwide will benefit from the extensive effort to understand the shared features and geographic diversity of the human genome."

In addition to The Genome Institute, other research centers involved in the project include: the Human Genome Sequencing Center at the Baylor College of Medicine, Houston; The Broad Institute of MIT and Harvard University in Cambridge, Mass., the Wellcome Trust Sanger Institute in England; BGI Shenzhen in China; the Max Planck Institute for Molecular Genetics in Berlin; and Illumina, Inc., in San Diego.

The research is supported, in part, by a grant (U54HG3079) from the National Human Genome Research Institute at the National Institutes of Health (NIH) to The Genome Institute at Washington University in St. Louis. Other funding sources include: the Wellcome Trust; Medial Research Council; British Heart Foundation; National Basic Research Program of China; the National Natural Science Foundation of China; the Max Planck Society; Swiss National Science Foundation.
The 1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes. Nature. Oct. 31, 2012
Source: Science Daily and Nature

Sunday, November 4, 2012

Scientific Roots of Disease

Global Genome Effort Seeks Genetic Roots of Disease


By decoding the genomes of more than 1,000 people whose homelands stretch from Africa and Asia to Europe and the Americas, scientists have compiled the largest and most detailed catalog yet of human genetic variation. The massive resource will help medical researchers find the genetic roots of rare and common diseases in populations worldwide. (Credit: National Human Genome Research Institute)

ScienceDaily (Oct. 31, 2012) — By decoding the genomes of more than 1,000 people whose homelands stretch from Africa and Asia to Europe and the Americas, scientists have compiled the largest and most detailed catalog yet of human genetic variation. The massive resource will help medical researchers find the genetic roots of rare and common diseases in populations worldwide.


The 1000 Genomes Project involved some 200 scientists at Washington University School of Medicine in St. Louis and other institutions. Results detailing the DNA variations of individuals from 14 ethnic groups are published Oct. 31 in the journal Nature. Eventually, the initiative will involve 2,500 individuals from 26 populations.

"With this resource, researchers have a roadmap to search for the genetic origins of diseases in populations around the globe," says one of the study's co-principal investigators, Elaine Mardis, PhD, co-director of The Genome Institute at Washington University. "We estimate that each person carries up to several hundred rare DNA variants that could potentially contribute to disease. Now, scientists can investigate how detrimental particular rare variants are in different ethnic groups."

At the genetic level, any two people are more than 99 percent alike. But rare variants -- those that occur with a frequency of 1 percent or less in a population -- are thought to contribute to rare diseases as well as common conditions like cancer, heart disease and diabetes. Rare variants may also explain why some medications are not effective in certain people or cause side effects such as nausea, vomiting, insomnia and sometimes even heart problems or death.
Identifying rare variants across different populations is a major goal of the project.

During the pilot phase of the effort, the researchers found that most rare variants differed from one population to another, and that they developed recently in human evolutionary history, after populations in Europe, Africa, Asia and the Americas diverged from a single group. The current study bears this out.

"This information is crucial and will improve our interpretation of individual genomes," says another of the study's co-principal investigators, Richard K. Wilson, PhD, director of The Genome Institute and a pioneer in cancer genome sequencing. "Now, if we want to study cancer in Mexican Americans or Japanese Americans, for example, we can do so in the context of their diverse geographic or ancestry-based genetic backgrounds."

Results of the new study are based on DNA sequencing of the following populations: Yoruba in Nigeria; Han Chinese in Beijing; Japanese in Tokyo; Utah residents with ancestry from northern and western Europe; Luhya in Kenya; people of African ancestry in the southwestern United States; Toscani in Italy; people of Mexican ancestry in Los Angeles; Southern Han Chinese in China; Iberian from Spain; British in England and Scotland; Finnish from Finland; Colombians in Columbia; and Puerto Rican in Puerto Rico.

All study participants submitted anonymous DNA samples and agreed to have their genetic data included in an online database. To catalog the variants, the researchers first sequenced the entire genome -- all the DNA -- of each individual in the study about five times. Surveying the genome in this way finds common DNA changes but misses many rare variants.

Then, to find rare variants, they repeatedly sequenced the small portion of the genome that contains genes -- about 80 times for each participant to ensure accuracy -- and they looked closely for single letter changes in the DNA sequence called SNPs (for single-nucleotide polymorphisms).

Using special tools developed to analyze and integrate the data, the researchers discovered a total of 38 million SNPs, including more than 99 percent of the variants with at frequency of at least one percent in the participants' DNA samples. They also found numerous structural variations, including 1.4 million short stretches of insertions or deletions and 14,000 large DNA deletions.

SNPs and structural variants can help explain an individual's susceptibility to disease, response to drugs or reaction to environmental factors such as air pollution or stress. Other studies have found an association between small insertions and deletions and diseases such as autism and schizophrenia.

The 1000 Genomes Project has generated massive amounts of genomic data. Simply recording the raw information took up some 180 terabytes of hard-drive space, enough to fill more than 40,000 DVDs. All of the information is freely available on the Internet through public databases.

"This tremendous resource builds on the knowledge of the Human Genome Project," says co-author George Weinstock, PhD, associate director of The Genome Institute. "Scientists and, ultimately, patients worldwide will benefit from the extensive effort to understand the shared features and geographic diversity of the human genome."

In addition to The Genome Institute, other research centers involved in the project include: the Human Genome Sequencing Center at the Baylor College of Medicine, Houston; The Broad Institute of MIT and Harvard University in Cambridge, Mass., the Wellcome Trust Sanger Institute in England; BGI Shenzhen in China; the Max Planck Institute for Molecular Genetics in Berlin; and Illumina, Inc., in San Diego.

The research is supported, in part, by a grant (U54HG3079) from the National Human Genome Research Institute at the National Institutes of Health (NIH) to The Genome Institute at Washington University in St. Louis. Other funding sources include: the Wellcome Trust; Medial Research Council; British Heart Foundation; National Basic Research Program of China; the National Natural Science Foundation of China; the Max Planck Society; Swiss National Science Foundation.

The 1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes. Nature. Oct. 31, 2012.


Story Source:
The above story is reprinted from materials provided by Washington University in St. Louisvia Newswise.

Thursday, October 4, 2012

Fast Genetic Test


Newborns may benefit from fast genetic test

Genome sequencing is rapidly changing modern medicine, and a new study shows its potential impact on seriously ill newborn babies.

New research published in the journal Science Translational Medicine this week makes the case for a two-day whole-genome sequencing for newborns in a neonatal intensive care unit (NICU).

After 50 hours, the test delivers to doctors a wealth of information about what could be causing newborns’ life-threatening illnesses. This would allow them to more efficiently and quickly tailor therapies to the babies, when possible, and identify problematic genetic variants that multiple family members may share.

“We think this is going to transform the world of neonatology, by allowing neonatologists to practice medicine that’s influenced by genomes,” said Stephen Kingsmore, the study's senior author and director for the Center for Pediatric Genomic Medicine at Children’s Mercy Hospitals and Clinics in Kansas City, Missouri, at a press conference Tuesday.

There are more than 3,500 diseases caused by a mutation in a single gene, Kingsmore said, and only about 500 have treatments. About one in 20 babies born in the United States annually gets admitted to a neonatal intensive care unit, he said. Genetic-driven illnesses are a leading cause of these admissions at Kingsmore’s hospital.

One example of how a genetic test would help newborns is a condition called severe Pompe disease, Kingsmore said. Children with this disorder die if they are not treated by age one.

They will live longer, at least four years, if they receive an enzyme replacement therapy.
The study shows how two software programs, called SAGA and RUNE, work together to help physicians pinpoint the genes that could be causing problems in the children. A company called Illumina developed a rapid genome sequencing device that incorporates the programs.
Researchers reported diagnoses as a result of this genetic test in the study for six children. Two of these tests were done retrospectively, after the children had died.

The test extends beyond the ill baby; genome sequencing can also identify genetic traits in multiple family members, the researchers said. Carol Saunders, the study's lead author, explained at the news conference how one baby and his 6-year-old brother both have a congenital heart defect and heterotaxy, meaning some internal organs are located on the wrong side of the body.

While some children will still die from incurable genetic disorders after being tested for them, the knowledge about diagnosis and likely outcomes for future children is beneficial for parents, experts say.

“Knowing the marker or defect may provide some information regarding the prognosis so the family knows what to expect,” Saunders said. "Importantly, it also allows them to have accurate genetic counseling regarding their risk to have another affected baby, and to make informed decisions about their reproductive future.”

Families value the diagnoses derived from this genetic test because it gives an answer, and alleviates guilt that something happened during pregnancy, Kingsmore said in an e-mail.
“It gives time for maternal bonding and saying goodbyes and last rites that can be planned,” Kingsmore said. “This is all complex but very real.”

The test costs roughly $13,500, but costs of whole-genome sequencing are quickly falling – experts believe a $1,000 genome sequence is not far off, Kingsmore said.
Children’s Mercy Hospital plans to offer this testing before the end of the year. Next year, Kingsmore and colleagues plans to offer testing at other hospitals for NICU patients.
Kingsmore estimates that about 5,000 babies a year could benefit from this technology.
“Ultimately, it will be used for every child with an illness that may be due to a genetic disease,” he said.It made sense to start with the NICU because of the costs involved, he said.

Source: CNN. Interesting note: This story appeared specifically on Fox News Latino.